KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) (2018 - 2025)

Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.24 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 136.92% year-over-year to -$0.24, compared with a TTM value of $1.78 through Dec 2025, down 19.46%, and an annual FY2025 reading of $1.8, down 18.55% over the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.24 at Biomarin Pharmaceutical, down from -$0.16 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.23 in Q2 2025, with the low at -$0.32 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.26, with a median of $0.18 recorded in 2022.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 390.91% in 2021 and then surged 7688.88% in 2023.
  • Tracing BMRN's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.32 in 2021, then surged by 99.59% to -$0.0 in 2022, then surged by 7688.88% to $0.1 in 2023, then skyrocketed by 550.0% to $0.65 in 2024, then crashed by 136.92% to -$0.24 in 2025.
  • Per Business Quant, the three most recent readings for BMRN's EPS (Weighted Average and Diluted) are -$0.24 (Q4 2025), -$0.16 (Q3 2025), and $1.23 (Q2 2025).